eplex blood culture identification fungal pathogen (bcid-fp) (GenMark Diagnostics)
90
Structured Review
GenMark Diagnostics
eplex blood culture identification fungal pathogen (bcid-fp)
Eplex Blood Culture Identification Fungal Pathogen (Bcid Fp), supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eplex+blood+culture+identification+fungal+pathogen+(bcid-fp)/eplex+blood+culture+identification+fungal+pathogen+panel/pm39857024-40-4-21
Average 90 stars, based on 1 article reviews
Eplex Blood Culture Identification Fungal Pathogen (Bcid Fp), supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eplex+blood+culture+identification+fungal+pathogen+(bcid-fp)/eplex+blood+culture+identification+fungal+pathogen+panel/pm39857024-40-4-21
Average 90 stars, based on 1 article reviews
eplex blood culture identification fungal pathogen (bcid-fp) - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Extraction:Article Title: 9th Trends in Medical Mycology Held on 11–14 October 2019, Nice, France, Organized under the Auspices of EORTC-IDG and ECMM Article Snippet: Delay of effective antifungal treatment is associated with unfavorable outcome and rapid species identification contributes to adapt antifungal therapy. Article Title: Candida auris : A Continuing Threat. Article Snippet: In contrast, commercially available FDA-cleared/-approved tests such as the Article Title: Updates on the profile of GenMark's ePlex blood culture identification fungal pathogen panel. Article Snippet: Introduction: The clinical and economical burdens of invasive fungal diseases (IFDs) remain substantial despite advances in diagnostics and therapeutics.. Major challenges in diagnosis of IFDs are difficulty in obtaining appropriate specimens for histopathology examination and prolonged turnaround time for fungal cultures.. Molecular assays for direct detection of fungal DNA from sterile sites such as blood can provide definitive diagnosis of IFDs in a reduced turnaround time. Article Title: 181. Impact of Rapid Diagnostic Technology on Patients with Candidemia Article Snippet: The objective of this study was to evaluate the clinical impact of the Article Title: Multicenter Evaluation of a PCR-Based Digital Microfluidics and Electrochemical Detection System for the Rapid Identification of 15 Fungal Pathogens Directly from Positive Blood Cultures Article Snippet: The Article Title: Candida auris —a systematic review to inform the world health organization fungal priority pathogens list Article Snippet: There are several FDA-approved molecular tests such as (i) Bruker Biotyper brand MALDI-TOF using the updated Bruker FDA-approved MALDI Biotyper CA System library (Version Claim 4), (ii) bioMérieux VITEK (MALDI-TOF) MS using the Article Title: Current Updates on Molecular Diagnostic Assays Used for Detection of Candida auris : A Systematic Review Article Snippet: Currently, there are two US Food and Drug Administration (FDA)-approved molecular assays validated for testing on positive Amplification:Article Title: 9th Trends in Medical Mycology Held on 11–14 October 2019, Nice, France, Organized under the Auspices of EORTC-IDG and ECMM Article Snippet: Delay of effective antifungal treatment is associated with unfavorable outcome and rapid species identification contributes to adapt antifungal therapy. Article Title: Candida auris : A Continuing Threat. Article Snippet: In contrast, commercially available FDA-cleared/-approved tests such as the Article Title: Updates on the profile of GenMark's ePlex blood culture identification fungal pathogen panel. Article Snippet: Introduction: The clinical and economical burdens of invasive fungal diseases (IFDs) remain substantial despite advances in diagnostics and therapeutics.. Major challenges in diagnosis of IFDs are difficulty in obtaining appropriate specimens for histopathology examination and prolonged turnaround time for fungal cultures.. Molecular assays for direct detection of fungal DNA from sterile sites such as blood can provide definitive diagnosis of IFDs in a reduced turnaround time. Article Title: 181. Impact of Rapid Diagnostic Technology on Patients with Candidemia Article Snippet: The objective of this study was to evaluate the clinical impact of the Article Title: Multicenter Evaluation of a PCR-Based Digital Microfluidics and Electrochemical Detection System for the Rapid Identification of 15 Fungal Pathogens Directly from Positive Blood Cultures Article Snippet: The Article Title: Candida auris —a systematic review to inform the world health organization fungal priority pathogens list Article Snippet: There are several FDA-approved molecular tests such as (i) Bruker Biotyper brand MALDI-TOF using the updated Bruker FDA-approved MALDI Biotyper CA System library (Version Claim 4), (ii) bioMérieux VITEK (MALDI-TOF) MS using the Article Title: Current Updates on Molecular Diagnostic Assays Used for Detection of Candida auris : A Systematic Review Article Snippet: Currently, there are two US Food and Drug Administration (FDA)-approved molecular assays validated for testing on positive Hybridization:Article Title: 9th Trends in Medical Mycology Held on 11–14 October 2019, Nice, France, Organized under the Auspices of EORTC-IDG and ECMM Article Snippet: Delay of effective antifungal treatment is associated with unfavorable outcome and rapid species identification contributes to adapt antifungal therapy. Article Title: Candida auris : A Continuing Threat. Article Snippet: In contrast, commercially available FDA-cleared/-approved tests such as the Article Title: Updates on the profile of GenMark's ePlex blood culture identification fungal pathogen panel. Article Snippet: Introduction: The clinical and economical burdens of invasive fungal diseases (IFDs) remain substantial despite advances in diagnostics and therapeutics.. Major challenges in diagnosis of IFDs are difficulty in obtaining appropriate specimens for histopathology examination and prolonged turnaround time for fungal cultures.. Molecular assays for direct detection of fungal DNA from sterile sites such as blood can provide definitive diagnosis of IFDs in a reduced turnaround time. Article Title: 181. Impact of Rapid Diagnostic Technology on Patients with Candidemia Article Snippet: The objective of this study was to evaluate the clinical impact of the Article Title: Multicenter Evaluation of a PCR-Based Digital Microfluidics and Electrochemical Detection System for the Rapid Identification of 15 Fungal Pathogens Directly from Positive Blood Cultures Article Snippet: The Article Title: Candida auris —a systematic review to inform the world health organization fungal priority pathogens list Article Snippet: There are several FDA-approved molecular tests such as (i) Bruker Biotyper brand MALDI-TOF using the updated Bruker FDA-approved MALDI Biotyper CA System library (Version Claim 4), (ii) bioMérieux VITEK (MALDI-TOF) MS using the Article Title: Current Updates on Molecular Diagnostic Assays Used for Detection of Candida auris : A Systematic Review Article Snippet: Currently, there are two US Food and Drug Administration (FDA)-approved molecular assays validated for testing on positive |